Compare TONX & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TONX | VTVT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0M | 148.7M |
| IPO Year | N/A | 2015 |
| Metric | TONX | VTVT |
|---|---|---|
| Price | $3.98 | $33.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | ★ 543.3K | 29.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.75 | $14.00 |
| 52 Week High | $8.23 | $44.00 |
| Indicator | TONX | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 44.76 |
| Support Level | $2.96 | $30.09 |
| Resistance Level | $4.31 | $33.11 |
| Average True Range (ATR) | 0.48 | 2.60 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 85.50 | 32.56 |
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.